Chief Financial Officer – Transformation — Diagnostic-Services Platform

The mandate

A diagnostic-services platform is investing rapidly in specimen identity, critical-result communication and laboratory information controls. The transformation programme ledger combines remediation, routine replacement and growth. The board needs an urgent replacement CFO who can protect the control build while restoring an investable economic baseline.

Approximately 1,100 employees and material partners span collection, transport, laboratories, imaging, pathology, reporting, technology, quality and commercial support in Singapore and connected markets. The CFO – Transformation owns finance, programme assurance, cash, control, procurement economics and decision support. The role reports to the Group Chief Executive and relevant board committee, partnering closely with clinical, laboratory and quality officers whose independent safety authority must be preserved.

The CFO will first separate the investment book. Work required to contain a current patient risk must not compete with discretionary growth on an undifferentiated return threshold. Conversely, labelling every systems request as safety-critical cannot bypass design discipline. Each initiative needs a documented hazard, control objective, accountable clinical owner, delivery cost, operating consequence and verification route.

Specimen identity is the first economic case. Barcoding, accessioning, aliquoting, analyser interfaces and manual exceptions form one chain; strengthening a single link can merely move failure downstream. Finance will test full-process cost, including recollection, courier runs, delayed treatment, investigation time and lost capacity. Benefits must be measured as reliable risk reduction and flow, not software installation.

Critical results require equally clear ownership. A result released from a laboratory has not completed its purpose until the responsible clinician receives, acknowledges and acts upon it. The CFO will fund and track escalation controls without allowing programme accounting to count message transmission as clinical closure. Uncontactable recipients, after-hours pathways and amended reports need costed operating designs.

The transformation baseline must become auditable. Existing plans contain overlapping savings, optimistic timing and benefits that depend on the same staff hours. The CFO will create a single benefits register with counterfactuals, dependencies and evidence owners. Savings will enter the forecast only after they are realised in headcount, purchasing, capacity or cash; avoided harm will be reported separately and with methodological restraint.

Platform unit economics will connect test families to collection, transport, processing, interpretation, reporting and exception burden. Average cost per test hides low-volume specialist work and repeat testing caused by pre-analytical failure. The CFO must expose cross-subsidies and capacity constraints while ensuring that economic analysis never pressures authorised professionals to narrow necessary testing.

Working capital includes more than receivables. Reagents, calibrators, controls and consumables carry expiry, lot, cold-chain and minimum-order constraints. Procurement savings that create excess stock or analyser incompatibility are false value. Finance will work with laboratories to distinguish safety stock from unmanaged accumulation and to quantify the continuity risk of sole-source materials.

The close and control environment also need repair. Transformation costs are being capitalised inconsistently, supplier milestones do not always match accepted delivery and manual journals obscure programme overruns. The CFO will establish clear accounting policies, milestone evidence and balance-sheet ownership. No programme leader may validate both completion and benefit achievement without independent challenge.

Commercial choices require sharper evidence. Payer tenders and provider contracts often price a test without the collection and reporting complexity around it. The CFO will ensure bids reflect service levels, specialist interpretation, logistics, recollection exposure and inflation. Attractive volume that consumes a scarce analyser window or specialist workforce must be assessed on constrained contribution rather than headline revenue.

The role inherits committed vendors and partially deployed systems. Abrupt cancellation could add safety risk; passive continuation could waste capital. The CFO will conduct contract-by-contract reviews of deliverables, acceptance, intellectual property, data protection, exit rights and clinical dependency. Renegotiation will follow evidence, with continuity safeguards agreed before leverage is used.

Board communication must keep safety and finance distinct but connected. The committee should see whether the control is working, whether delivery remains affordable and which assumption changed. A green budget cannot compensate for a weak clinical control, and a well-designed control does not excuse an unmanaged programme. The CFO will insist on both truths.

What you will own

• Transformation funding, programme finance and independent benefits assurance.
• Finance, cash, accounting policy and board-committee reporting.
• Patient-safety investment cases with clinical control owners.
• Diagnostic test-family and constrained-capacity economics.
• Inventory, procurement, supplier and continuity analysis.
• Contract, milestone, capitalisation and acceptance controls.
• Revenue quality, bids and payer profitability.
• Finance and programme-assurance leadership succession.

The first 12 months

In the first 40 days, reconcile committed transformation spend, identify unsupported benefits and trace the highest-risk specimen and critical-result controls from hazard to verification. Present a revised funding envelope without interrupting essential safeguards.

By month six, operate one programme ledger, complete priority test-family economics and embed independent milestone acceptance. Resolve major capitalisation and supplier-control weaknesses.

At twelve months, achieve 95% evidence-backed benefit reporting, reduce specimen recollection attributable to identity or handling by 35% and cut critical-result acknowledgement exceptions by 60%. Release SGD 35 million of cash or recurring cost without removing a required safety control, and complete the monthly close within six working days with no material unsupported programme balance.

What the committee will inspect

• Safety investments linked to explicit hazards and verification.
• Benefits counted once and only after demonstrable change.
• Test economics reflecting exceptions and scarce capacity.
• Inventory choices balancing expiry with continuity.
• Supplier payments tied to accepted, usable outcomes.
• Finance challenge that respects clinical independence.

The person

You bring 22–28 years in finance and transformation, including CFO-level responsibility in diagnostics, laboratories, healthcare technology, medical devices or another safety-critical service. Your record should include a control remediation funded through a complex programme, as well as statutory finance, cash and board assurance.

You can discuss specimen workflow with laboratory leaders, interrogate a systems milestone and explain accounting judgement to an audit committee. Singapore experience and regional supplier exposure are required. This is an onsite appointment because evidence must be tested where diagnostic work and transformation delivery occur.

Compensation and terms

Base compensation is SGD 420,000–570,000 plus annual incentive and long-term participation measured against control verification, cash, benefits integrity, close quality and team renewal. The permanent role is onsite in Singapore, reporting to the Group Chief Executive and relevant board committee. Replacement timing is urgent, with an orderly evidence handover required.

Confidentiality

The platform, laboratories, test portfolio, clinical findings, suppliers, systems and financial programme data are confidential. Access follows conflict clearance and signed confidentiality. Candidates must not contact diagnostic providers, vendors or practitioners in an attempt to identify the client.